Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $73.94 -1.36%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $20.63 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Putin Said To Plan Ukraine Escalation, Seeing Talks Fruitless - Bloomberg
- Hormel Foods (HRL) call put ratio 1 call to 1.1 puts into quarter results
- Movado Group (MOV) Tops Q2 EPS by 19c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
